Literature DB >> 10594748

Accumulation of identical T cells in melanoma and vitiligo-like leukoderma.

J C Becker1, P Guldberg, J Zeuthen, E B Bröcker, P T Straten.   

Abstract

The cloning of genes encoding melanoma antigens has opened new possibilities for the treatment of patients with cancer; however, most tumor rejection antigens recognized by tumor infiltrating lymphocytes are the products of genes that are also expressed by normal melanocytes. Hence, a large set of antigenic determinants of the self have not induced self-tolerance and these peptide determinants furnish target structures for immune responses directed against tumors. The notion that the immunotherapeutic targets involved in cancer regression comprise normal differentiation antigens is stressed by the association between vitiligo-like leukoderma, due to destruction of normal melanocytes, and melanoma regression, due to destruction of cancer cells. Nevertheless, this is the first report to demonstrate by means of a new technique based on reverse transcription polymerase chain reaction and denaturing gradient gel electrophoresis, the presence of clonally expanded T cells with identical BV regions in areas of destruction of both normal and neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594748     DOI: 10.1046/j.1523-1747.1999.00805.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

Review 1.  Modern aspects of vitiligo pathogenesis.

Authors:  I M Korsunskaya; K N Suvorova; E V Dvoryankova
Journal:  Dokl Biol Sci       Date:  2003 Jan-Feb

Review 2.  Hypopigmentary skin disorders: current treatment options and future directions.

Authors:  Anke Hartmann; Eva-B Bröcker; Jürgen C Becker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Melanoma-associated leukoderma - immunology in black and white?

Authors:  Hadas Prag Naveh; Uma N M Rao; Lisa H Butterfield
Journal:  Pigment Cell Melanoma Res       Date:  2013-10-09       Impact factor: 4.693

4.  The dark side of immunotherapy: challenges facing the new hope in cancer treatment.

Authors:  Eduard Teixidor; Joaquim Bosch-Barrera
Journal:  Ann Transl Med       Date:  2019-09

5.  CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.

Authors:  R M Kedl; M Jordan; T Potter; J Kappler; P Marrack; S Dow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

6.  Epidermotropic metastatic melanoma with perilesional depigmentation in an Indian male.

Authors:  Bhavana Doshi; Sunanda Mahajan; Uday S Khopkar; Vidya Kharkar; Prachi Agarwal
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

7.  Paradoxes in dermatology.

Authors:  Keshavmurthy A Adya; Arun C Inamadar; Aparna Palit
Journal:  Indian Dermatol Online J       Date:  2013-04

8.  Th17 cells and activated dendritic cells are increased in vitiligo lesions.

Authors:  Claire Q F Wang; Andres E Cruz-Inigo; Judilyn Fuentes-Duculan; Dariush Moussai; Nicholas Gulati; Mary Sullivan-Whalen; Patricia Gilleaudeau; Jules A Cohen; James G Krueger
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

Review 9.  New perspectives on the role of vitiligo in immune responses to melanoma.

Authors:  Katelyn T Byrne; Mary Jo Turk
Journal:  Oncotarget       Date:  2011-09

10.  Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin.

Authors:  Jared Klarquist; Jonathan M Eby; Steven W Henning; Mingli Li; Derek A Wainwright; Wiete Westerhof; Rosalie M Luiten; Michael I Nishimura; I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2016-03-04       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.